Literature DB >> 9103416

A kinase-negative mutation of DNA-PK(CS) in equine SCID results in defective coding and signal joint formation.

E K Shin1, L E Perryman, K Meek.   

Abstract

The equine SCID defect is more severe than its murine counterpart in that SCID foals are incapable of forming either coding or signal joints, whereas SCID mice manifest normal signal joint formation. To determine the basis of this difference and whether DNA-dependent kinase, catalytic subunit (DNA-PK(CS)), is involved in signal joint formation, equine DNA-PK(CS) transcripts were cloned and sequenced from normal and SCID cell lines. In the mutant allele, a frame-shift mutation truncates the protein N terminal of the domain with homology to the phosphatidylinositol 3-kinase family resulting in complete absence of full length DNA-PK(CS) and accounting for the kinase-negative phenotype of these cells; the mutation in SCID mice allows for some DNA-PK(CS) expression. The difference in DNA-PK(CS) expression in SCID mice and foals explains the more severe phenotype of equine SCID, and definition of DNA-PK(CS) as the defect in equine SCID demonstrates that DNA-PK(CS) is required for both coding and signal joint formation.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9103416

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  A single amino acid substitution in DNA-PKcs explains the novel phenotype of the CHO mutant, XR-C2.

Authors:  Timothy Woods; Wei Wang; Erin Convery; Abdellatif Errami; Malgorzata Z Zdzienicka; Katheryn Meek
Journal:  Nucleic Acids Res       Date:  2002-12-01       Impact factor: 16.971

2.  Deciphering phenotypic variance in different models of DNA-PKcs deficiency.

Authors:  Jessica A Neal; Katheryn Meek
Journal:  DNA Repair (Amst)       Date:  2018-10-30

3.  Analysis of variable (diversity) joining recombination in DNAdependent protein kinase (DNA-PK)-deficient mice reveals DNA-PK-independent pathways for both signal and coding joint formation.

Authors:  M A Bogue; C Jhappan; D B Roth
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-22       Impact factor: 11.205

4.  XR-C1, a new CHO cell mutant which is defective in DNA-PKcs, is impaired in both V(D)J coding and signal joint formation.

Authors:  A Errami; D M He; A A Friedl; W J Overkamp; B Morolli; E A Hendrickson; F Eckardt-Schupp; M Oshimura; P H Lohman; S P Jackson; M Z Zdzienicka
Journal:  Nucleic Acids Res       Date:  1998-07-01       Impact factor: 16.971

5.  Molecular and biochemical characterisation of DNA-dependent protein kinase-defective rodent mutant irs-20.

Authors:  A Priestley; H J Beamish; D Gell; A G Amatucci; M C Muhlmann-Diaz; B K Singleton; G C Smith; T Blunt; L C Schalkwyk; J S Bedford; S P Jackson; P A Jeggo; G E Taccioli
Journal:  Nucleic Acids Res       Date:  1998-04-15       Impact factor: 16.971

6.  A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining.

Authors:  Mirjam van der Burg; Hanna Ijspeert; Nicole S Verkaik; Tuba Turul; Wouter W Wiegant; Keiko Morotomi-Yano; Pierre-Olivier Mari; Ilhan Tezcan; David J Chen; Malgorzata Z Zdzienicka; Jacques J M van Dongen; Dik C van Gent
Journal:  J Clin Invest       Date:  2008-12-15       Impact factor: 14.808

7.  The ATM Kinase Restrains Joining of Both VDJ Signal and Coding Ends.

Authors:  Katheryn Meek; Yao Xu; Caleb Bailie; Kefei Yu; Jessica A Neal
Journal:  J Immunol       Date:  2016-08-29       Impact factor: 5.422

8.  Potential large animal models for gene therapy of human genetic diseases of immune and blood cell systems.

Authors:  Thomas R Bauer; Rima L Adler; Dennis D Hickstein
Journal:  ILAR J       Date:  2009

Review 9.  Applied equine genetics.

Authors:  C J Finno; D L Bannasch
Journal:  Equine Vet J       Date:  2014-06-25       Impact factor: 2.888

10.  DNA-PK is essential only for coding joint formation in V(D)J recombination.

Authors:  P Kulesza; M R Lieber
Journal:  Nucleic Acids Res       Date:  1998-09-01       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.